建立了顶空采样-毛细管气相色谱检测格列美脲原料药中溶剂残留的分析方法.对产自国内8个生产厂家的格列美脲样品中有机溶剂的残留状况进行了系统评价,结合药品生产工艺信息,确定了丙酮、乙酸乙酯、甲醇、异丙醇、乙醇、氯仿、甲苯、1,4-二氧六环、吡啶、氯苯、乙醚、二氯甲烷、正己烷和苯等14种有机溶剂为残留检测对象.根据被测组分在色谱柱上的保留性质将其分为两类,以实现基线分离.用Supelco-Wax极性色谱柱,以乙腈为内标物,分离检测了丙酮、乙酸乙酯、甲醇、异丙醇、乙醇、氯仿、甲苯、1,4-二氧六环、吡啶和氯苯的残留量;用Supelco OVI-G43弱极性色谱柱,以丁酮为内标,分离检测了乙醚、二氯甲烷、正己烷和苯的残留量.14种残留组分在各自的浓度范围内呈良好的线性关系(r=0.991 67~0.999 97,n=8),最低检出限范围为0.2~13.5 μg/g;14种残留组分检测的日间重复性(以相对标准偏差(RSD)计)为0.6% ~9.2%(n=3),3种加标浓度的平均添加回收率为86.3% ~104.1%(RSD为0.2% ~5.3%,n=16).实验结果表明,该方法简单、灵敏、可靠,适用于格列美脲中残留溶剂的分析确证.
An analytical method for the solvent residues in the raw material drug of glimepiride has been established by head-space sampling capillary gas chromatography. General evaluation was made for the distribution of organic residual solvents in glimepiride samples from 8 differ-ent domestic manufacturers. Based on the evaluation-test results and the information provided by manufacturers, 14 target solvents were ascertained including acetone, ethyl acetate, metha-nol, isopropanol, ethanol, chloroform, toluene, 1,4-dioxane, pyridine, chlorobenzene, ether, dichloromethane, n-hexane and benzene. The target solvents were divided into two groups for baseline separation according to their column-retention specificity. Acetone, ethyl acetate, methanol, isopropanol, ethanol, chloroform, toluene, 1,4-dioxane, pyridine and chloroben-zene were separated on a Supelco-Wax capillary column with acetonitrile as internal standard, while ether, dichloromethane, n-hexane and benzene were determined on a Supelco OVI-G43 capillary column with butanone as internal standard. Linear responses were obtained for the 14 residual solvents in their respective concentration ranges (r = 0. 991 67 - 0. 999 97 , n = 8), and the limits of detection were 0. 2-13. 5 μg/g. The inter-day reproducibilities, measured as rela-tive standard deviations (RSDs), were 0. 6%-9. 2% (n = 3). The average recoveries of three concentration levels were 86. 3%-104. 1% with the RSD of 0. 2% -5. 3% (N = 16). The devel-oped method is simple, sensitive, and accurate for the residual solvent analysis in glimepiride samples.
参考文献
[1] | Steering Committee of ICH.Zhou H J,transl.Technical requirements for registration of pharmaceuticals for human use:section of quality.Beijing:People's Medical Publishing House (ICH指导委员会.周海钧,译.药品注册的国际技术要求:质量部分.北京:人民卫生出版社),2000 |
[2] | Liu J,Li J H,Chen G L.Chinese Journal of Pharmaceutical Analysis (刘瑾,李建华,陈桂良.药物分析杂志),2006,26(1):120 |
[3] | Liu D,Duan P,Zhang J Q.Chinese Journal of Pharmaceutical Analysis (刘冬,段平,张静秋.药物分析杂志),2006,26(2):247 |
[4] | Zhang W S,Song X T,Wu S S.Chinese Journal of Pharmaceutical Analysis (张文生,宋晓涛,武珊珊.药物分析杂志),2006,26(3):393 |
[5] | Wang Y,Yang L,Yuan J,et al.Chinese Journal of Pharmaceutical Analysis (王野,杨蕾,袁军,等.药物分析杂志),2006,26(3):396 |
[6] | Jiang G Q.Chinese Journal of Pharmaceutical Analysis (蒋国强.药物分析杂志),2006,26(4):523 |
[7] | Feng M X,Wang X Q,Liu J.Chinese Journal of Pharmaceutical Analysis (冯明霞,王雪芹,刘杰.药物分析杂志),2006,26(6):862 |
[8] | Xu B,Pei F J,Zhang W B,et al.Chinese Journal of Pharmaceutical Analysis (徐斌,裴付军,张维斌,等.药物分析杂志),2006,26(6):865 |
[9] | Liu Z W.Central South Pharmacy (刘志武.中南药学),2007,5(4):342 |
[10] | Li X H,Yang Z,Hu X W.Chinese Journal of New Drugs (李心泓,杨直,胡晓炜.中国新药杂志),2007,16(7):554 |
[11] | Zhou M H,Tao Q F,Xu S L,et al.Chinese Journal of Pharmaceutical Analysis (周明昊,陶巧凤,许胜龙,等.药物分析杂志),2008,28(5):810 |
[12] | Gao X R,Xu Y,Sun S M,et al.Qilu Pharmaceutical Affairs (高秀蕊,徐英,孙士民,等.齐鲁药事),2008,27(12):716 |
[13] | Ke Z F,Pei Q J.Chinese Journal of Modern Applied Pharmacy (柯正方,裴秋菊.中国现代应用药学杂志),2009,26(5):398 |
[14] | Yang B Y.China Pharmaceuticals (杨必勇.中国药业),2009,18(7):22 |
[15] | Chinese Pharmacopoeia Commission.Chinese Pharmacopoeia,2005.Vol Ⅱ.Beijing:People's Medical Publishing House (国家药典委员会.中国药典2005年版.二部.北京:人民卫生出版社),2005:Appendix Ⅷ P |
[16] | Hu C Q,Liu Y.Drug Standards of China (胡昌勤,刘颖.中国药品标准),2005,6(3):52 |
- 下载量()
- 访问量()
- 您的评分:
-
10%
-
20%
-
30%
-
40%
-
50%